# Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

> **NCT07130695** · PHASE1 · RECRUITING · sponsor: **Virginia Commonwealth University** · enrollment: 15 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Olutasidenib Investigational Agent Administration

## Key facts

- **NCT ID:** NCT07130695
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2028-10-31
- **Final completion:** 2030-10-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07130695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07130695, "Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07130695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*